Patient characteristics
| Interventional group (received CTLs) . | Observation group (did not receive CTLs) . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient number . | Age-race/ethnicity . | No. of prior vaccine/booster . | Day∗ symptoms definitely better . | Day∗ symptoms resolved . | Comorbid conditions . | CTL dosing level . | Variant† . | Patient number . | Age-race/ethnicity . | No. of prior vaccine/boosters . | Day∗ symptoms definitely better . | Day∗ symptoms resolved . | Comorbid conditions . | Alternate therapies . |
| Fall 2021 | ||||||||||||||
| 1♂ | 24-AA | None | 3 | 8 | DM, HTN, lung disease, obesity | 1 | Delta | 1♂ | 77-Cau | 2 | 23 | 180 | Age, HTN, obesity | Moab day +2, ICU/ventilator |
| 2♀ | 73-Cau | 2 | 3 | 13 | Age, HTN, Obesity | 1 | Delta | 2♀ | 65-Cau | 2 | 5 | 60 | Age, HTN, obesity | |
| 3♀‡ | 47-His | 1 | 2 | 6 | CAD, CVA, DM, HTN, SLE | 1 | Delta | 3♀ | 59-AA | 2 | 2 | 11 | DM, MI, obesity | Moab day 0 (After HLA typing was known) |
| 4♀ | 44-His | 2 | 3 | 7 | Obesity | Moab day +1 | ||||||||
| 5♂ | 53-AA | 2 | 7 | 9 | DM, HTN, obesity | Moab day +1 | ||||||||
| 6♀ | 51-Cau | None | 4 | 8 | DM, HTN, obesity | Moab day +1 | ||||||||
| End December 2021/January-March 2022 | ||||||||||||||
| 4♂‡ | 56-Cau | 2 | 2 | 10 | Colon Ca, obesity | 2 | Omicron BA.1 | 7♂ | 65-Cau | 3 | 4 | 14 | Age, HTN, obesity | |
| 5♀‡ | 44-His | None | 2 | 4 | Lymphoma, obesity | 2 | Omicron BA.1 | 8♂ | 61-AA | 2 | 6 | 14 | DM, HTN | |
| 6♀‡ | 73-Cau | 1 | 2 | 6 | Age, HTN, pancreatic Ca | 2 | Omicron BA.1 | 9♀ | 28-AA | 2 | 3 | 5 | HTN | |
| April-June 2022 | ||||||||||||||
| 7♂ | 58-Cau | 3 | 2 | 10 | HTN, DM | 3 | Omicron BA.2 | 10♀ | 68-Cau | 3 | 4 | 12 | Age | Nirmatrelvir/ritonavir day +2 |
| 8♀‡ | 83-Cau | 3-NMR | 2 | 9 | Age, HTN, lymphoma | 3 | Omicron BA.2 | 11♂ | 85-Cau | 3 | 5 | 11 | Age, DM, HTN | |
| 9♀‡ | 63-AA | 3-NMR | 2 | 7 | HTN, obesity, lymphoma, | 3 | Omicron BA.2 | 12♀ | 55-Cau | 4 | 3 | 9 | DM, HTN, obesity | |
| 10♂ | 67-Cau | 3 | 2 | 6 | Age, DM, HTN, AFib, obesity | 4 | Omicron BA.2 | 13♂ | 63-Cau | 2 | 5 | 9 | HTN, obesity | |
| 14♂ | 68-AA | 3 | 1 | 12 | Age, CVA, heart disease | |||||||||
| July 2022 | ||||||||||||||
| 11♀ | 60-Cau | None-COVID 6 mo prior | 3 | 11 | DM, HTN, obesity | 4 | Omicron BA.5 (presumed) | 15♀ | 40-Cau | 3 | 3 | 28 | HTN, obesity | |
| 12♂ | 49-Cau | 3 | 2 | 8 | DM, HTN, obesity | 4 | Omicron BA.5 | 16♀‡ | 26-Cau | 4 | 11 | 90 | Obesity, Behcet’s | |
| 17♂ | 55-Cau | 4 | 3 | 11 | HTN, obesity | |||||||||
| 18♀ | 54-Cau | 2 | 2 | 11 | obesity | |||||||||
| Interventional group (received CTLs) . | Observation group (did not receive CTLs) . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient number . | Age-race/ethnicity . | No. of prior vaccine/booster . | Day∗ symptoms definitely better . | Day∗ symptoms resolved . | Comorbid conditions . | CTL dosing level . | Variant† . | Patient number . | Age-race/ethnicity . | No. of prior vaccine/boosters . | Day∗ symptoms definitely better . | Day∗ symptoms resolved . | Comorbid conditions . | Alternate therapies . |
| Fall 2021 | ||||||||||||||
| 1♂ | 24-AA | None | 3 | 8 | DM, HTN, lung disease, obesity | 1 | Delta | 1♂ | 77-Cau | 2 | 23 | 180 | Age, HTN, obesity | Moab day +2, ICU/ventilator |
| 2♀ | 73-Cau | 2 | 3 | 13 | Age, HTN, Obesity | 1 | Delta | 2♀ | 65-Cau | 2 | 5 | 60 | Age, HTN, obesity | |
| 3♀‡ | 47-His | 1 | 2 | 6 | CAD, CVA, DM, HTN, SLE | 1 | Delta | 3♀ | 59-AA | 2 | 2 | 11 | DM, MI, obesity | Moab day 0 (After HLA typing was known) |
| 4♀ | 44-His | 2 | 3 | 7 | Obesity | Moab day +1 | ||||||||
| 5♂ | 53-AA | 2 | 7 | 9 | DM, HTN, obesity | Moab day +1 | ||||||||
| 6♀ | 51-Cau | None | 4 | 8 | DM, HTN, obesity | Moab day +1 | ||||||||
| End December 2021/January-March 2022 | ||||||||||||||
| 4♂‡ | 56-Cau | 2 | 2 | 10 | Colon Ca, obesity | 2 | Omicron BA.1 | 7♂ | 65-Cau | 3 | 4 | 14 | Age, HTN, obesity | |
| 5♀‡ | 44-His | None | 2 | 4 | Lymphoma, obesity | 2 | Omicron BA.1 | 8♂ | 61-AA | 2 | 6 | 14 | DM, HTN | |
| 6♀‡ | 73-Cau | 1 | 2 | 6 | Age, HTN, pancreatic Ca | 2 | Omicron BA.1 | 9♀ | 28-AA | 2 | 3 | 5 | HTN | |
| April-June 2022 | ||||||||||||||
| 7♂ | 58-Cau | 3 | 2 | 10 | HTN, DM | 3 | Omicron BA.2 | 10♀ | 68-Cau | 3 | 4 | 12 | Age | Nirmatrelvir/ritonavir day +2 |
| 8♀‡ | 83-Cau | 3-NMR | 2 | 9 | Age, HTN, lymphoma | 3 | Omicron BA.2 | 11♂ | 85-Cau | 3 | 5 | 11 | Age, DM, HTN | |
| 9♀‡ | 63-AA | 3-NMR | 2 | 7 | HTN, obesity, lymphoma, | 3 | Omicron BA.2 | 12♀ | 55-Cau | 4 | 3 | 9 | DM, HTN, obesity | |
| 10♂ | 67-Cau | 3 | 2 | 6 | Age, DM, HTN, AFib, obesity | 4 | Omicron BA.2 | 13♂ | 63-Cau | 2 | 5 | 9 | HTN, obesity | |
| 14♂ | 68-AA | 3 | 1 | 12 | Age, CVA, heart disease | |||||||||
| July 2022 | ||||||||||||||
| 11♀ | 60-Cau | None-COVID 6 mo prior | 3 | 11 | DM, HTN, obesity | 4 | Omicron BA.5 (presumed) | 15♀ | 40-Cau | 3 | 3 | 28 | HTN, obesity | |
| 12♂ | 49-Cau | 3 | 2 | 8 | DM, HTN, obesity | 4 | Omicron BA.5 | 16♀‡ | 26-Cau | 4 | 11 | 90 | Obesity, Behcet’s | |
| 17♂ | 55-Cau | 4 | 3 | 11 | HTN, obesity | |||||||||
| 18♀ | 54-Cau | 2 | 2 | 11 | obesity | |||||||||
AA, African American; AFib, atrial fibrillation; Ca, cancer; Cau, Caucasian; CAD, coronary artery disease; CVA, cerebral vascular accident; DM, diabetes mellitus; His, Hispanic; HTN, hypertension; MI, myocardial infarction; Moab, monoclonal antibody; NMR, no measurable response to vaccine; SLE, systemic lupus erythematosus.
Days to symptoms “definitely better” and days to health “back to baseline” both start from day 0.
SARS-CoV-2 variants analyzed for interventional group only.
Immune compromised due to cancer or autoimmune disease.